
Izvēlieties etiķeti
redzama tieši uz flakonaReta + Tesamorelin Blend
GLP-1
- Sūtām no Vācijas
Pasūtījums
- DHL ar izsekošanu
- Diskrēts iepakojums
Īsumā
Reta + Tesamorelin Blend skaitļos
Galvenie rādītāji no mūsu leksikona.
Pilns leksikona ieraksts- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Atsauksmes
Ko saka klienti
Tikai īsti pasūtījumi, kuros bija Reta + Tesamorelin Blend.
Visas atsauksmesProduktam Reta + Tesamorelin Blend vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes
Zināšanas
Viss par Reta + Tesamorelin Blend
Detalizēta informācija drīzumā.
Dozēšana
Ielādē dozēšanas informāciju …
Noderēs
Kas jums vēl būs vajadzīgs
Bakteriostatiskais ūdens tiek automātiski pievienots grozam. Šļirces un salvetes - ar vienu klikšķi.
Insulīna šļirces
10 gab. · 5.50 €
Spirta salvetes
50 gab. · 10 €
Cik daudz ūdens?
Vienības uz šļirces jūsu flakona izmēram.
Atvērt kalkulatoru →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Saistītie
Saistītie produkti
Tirzepatide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
10 izmēri
Laboratorijā pārbaudīts
= no 10 €/flakons
Retatrutide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
11 izmēri
Laboratorijā pārbaudīts
= no 16 €/flakons
Semaglutide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
6 izmēri
Laboratorijā pārbaudīts
= no 10 €/flakons
Mazdutide
Peptīdi · GLP-1 un tauku zudums GLP-1 un tauku zudums
2 izmēri
= no 32 €/flakons
Reta + Tesamorelin Blend